Table 1 Baseline characteristics in the overall population

From: Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials

Characteristic

Glycopyrronium (N = 1859)

Tiotropium (N = 1077)

Male (n; %)

1379 (74.18)

775 (71.96)

Age (years; SD)

63.9 (8.92)

63.7 (8.40)

BMI (kg/m2; SD)

26.5 (5.96)

26.6 (5.76)

Smoking status

 Ex-smoker (n; %)

1105 (59.44)

621 (57.66)

 Current smoker (n; %)

754 (40.56)

455 (42.29)

Duration of COPD, years (SD)

6.5 (5.93)

6.5 (5.73)

Exacerbation in previous 12 months (n; %)

449 (24.15)

272 (25.26)

Concomitant COPD medication (n; %)

 Short-acting anticholinergic

576 (30.98)

357 (33.15)

 Long-acting anticholinergic

180 (9.68)

97 (9.01)

 Short-acting beta-agonist

268 (14.42)

186 (17.27)

 Long-acting beta-agonist

760 (40.88)

483 (44.85)

 Inhaled corticosteroids

1015 (54.60)

594 (55.15)

 Combination LABA/ICS

647 (34.80)

422 (39.18)

 Combination LABA/LAMA

180 (9.68)

109 (10.12)

 Xanthine

167 (8.98)

91 (8.45)

SGRQ total score (SD)

48.0 (17.66)

48.2 (17.49)

BDI total score (SD)

6.2 (2.17)

6.3 (2.06)

Severity of airflow limitation (n; %)

 GOLD 1 (mild)

2 (0.11)

1 (0.09)

 GOLD 2 (moderate)

1148 (61.75)

661 (61.37)

 GOLD 3 (severe)

701 (37.71)

414 (38.44)

 GOLD 4 (very severe)

8 (0.43)

0 (0.00)

Comorbidities (n; %)

 Coronary artery bypass graft

10 (0.54)

5 (0.46)

 Myocardial infarction

29 (1.56)

32 (2.97)

 Stroke

21 (1.13)

14 (1.30)

 History of hypertension

352 (18.93)

366 (33.98)

 Type 2 Diabetes mellitus

93 (5.00)

86 (7.99)

FEV1, L (SD)

 Pre-bronchodilator

1.3 (0.47)

1.3 (0.48)

 Post-bronchodilator

1.5 (0.49)

1.5 (0.49)

FEV1, % Predicted (SD)

 Pre-bronchodilator

48.0 (13.44)

47.3 (13.45)

 Post-bronchodilator

54.9 (13.14)

55.0 (13.14)

FVC, L (SD)

 Pre-bronchodilator

2.8 (0.83)

2.8 (0.82)

 Post-bronchodilator

3.1 (0.89)

3.1 (0.85)

FEV1/FVC, % (SD)

 Pre-bronchodilator

48.1 (10.89)

47.4 (10.89)

 Post-bronchodilator

49.2 (10.63)

48.9 (10.69)

FEV1, Reversibility (%; SD)

16.7 (15.46)

18.6 (15.80)

FVC, Reversibility (%; SD)

13.6 (14.45)

14.8 (15.56)

Blood eosinophil count (cells/µL) (SD)

2.7 (1.84)

2.7 (1.76)

  1. Data are mean (SD) or n (%) unless otherwise stated
  2. BDI baseline dyspnea index, BMI body mass index, COPD chronic obstructive pulmonary disease, FEV 1 forced expiratory volume in 1 second, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, LABA long-acting beta-agonist, LAMA long-acting muscarinic agonist, o.d. once daily, SD standard deviation, SGRQ St George’s Respiratory Questionnaire
Back to article page